These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial. Guglielmetti L; Ardizzoni E; Atger M; Baudin E; Berikova E; Bonnet M; Chang E; Cloez S; Coit JM; Cox V; de Jong BC; Delifer C; Do JM; Tozzi DDS; Ducher V; Ferlazzo G; Gouillou M; Khan A; Khan U; Lachenal N; LaHood AN; Lecca L; Mazmanian M; McIlleron H; Moschioni M; O'Brien K; Okunbor O; Oyewusi L; Panda S; Patil SB; Phillips PPJ; Pichon L; Rupasinghe P; Rich ML; Saluhuddin N; Seung KJ; Tamirat M; Trippa L; Cellamare M; Velásquez GE; Wasserman S; Zimetbaum PJ; Varaine F; Mitnick CD Trials; 2021 Sep; 22(1):651. PubMed ID: 34563240 [TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of incorporating bedaquiline into a treatment regimen for MDR/XDR-TB in Germany. Wolfson LJ; Gibbert J; Wirth D; Diel R Eur Respir J; 2015 Dec; 46(6):1826-9. PubMed ID: 26493796 [No Abstract] [Full Text] [Related]
30. Current therapies for the treatment of multidrug-resistant tuberculosis in children in India. Mukherjee A; Lodha R; Kabra SK Expert Opin Pharmacother; 2017 Oct; 18(15):1595-1606. PubMed ID: 28847228 [TBL] [Abstract][Full Text] [Related]
31. Progress in global rollout of new multidrug-resistant tuberculosis treatments. Held K; McAnaw S; Chiang CY; Trebucq A; Horsburgh CR Int J Tuberc Lung Dis; 2019 Sep; 23(9):996-999. PubMed ID: 31615606 [No Abstract] [Full Text] [Related]
32. The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis. Hasan T; Medcalf E; Nyang'wa BT; Egizi E; Berry C; Dodd M; Foraida S; Gegia M; Li M; Mirzayev F; Morgan H; Motta I; Nguyen L; Schumacher S; Schlub T; Fox G Clin Infect Dis; 2024 Mar; 78(3):730-741. PubMed ID: 37874021 [TBL] [Abstract][Full Text] [Related]
33. Interim treatment outcomes in multidrug-resistant tuberculosis patients treated sequentially with bedaquiline and delamanid. Lee HH; Jo KW; Yim JJ; Jeon D; Kang H; Shim TS Int J Infect Dis; 2020 Sep; 98():478-485. PubMed ID: 32640367 [TBL] [Abstract][Full Text] [Related]
34. TB Alliance regimen development for multidrug-resistant tuberculosis. Murray S; Mendel C; Spigelman M Int J Tuberc Lung Dis; 2016 Dec; 20(12):38-41. PubMed ID: 28240571 [TBL] [Abstract][Full Text] [Related]
35. Tuberculosis: clinical trials and new drug regimens. Kwon YS; Jeong BH; Koh WJ Curr Opin Pulm Med; 2014 May; 20(3):280-6. PubMed ID: 24614239 [TBL] [Abstract][Full Text] [Related]
36. Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations. Hu M; Zheng C; Gao F Drug Des Devel Ther; 2016; 10():3983-3994. PubMed ID: 27994440 [TBL] [Abstract][Full Text] [Related]
37. Current and developing therapies for the treatment of multi drug resistant tuberculosis (MDR-TB) in India. Muniyandi M; Ramachandran R Expert Opin Pharmacother; 2017 Sep; 18(13):1301-1309. PubMed ID: 28786691 [TBL] [Abstract][Full Text] [Related]
38. Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort. Koirala S; Borisov S; Danila E; Mariandyshev A; Shrestha B; Lukhele N; Dalcolmo M; Shakya SR; Miliauskas S; Kuksa L; Manga S; Aleksa A; Denholm JT; Khadka HB; Skrahina A; Diktanas S; Ferrarese M; Bruchfeld J; Koleva A; Piubello A; Koirala GS; Udwadia ZF; Palmero DJ; Munoz-Torrico M; Gc R; Gualano G; Grecu VI; Motta I; Papavasileiou A; Li Y; Hoefsloot W; Kunst H; Mazza-Stalder J; Payen MC; Akkerman OW; Bernal E; Manfrin V; Matteelli A; Mustafa Hamdan H; Nieto Marcos M; Cadiñanos Loidi J; Cebrian Gallardo JJ; Duarte R; Escobar Salinas N; Gomez Rosso R; Laniado-Laborín R; Martínez Robles E; Quirós Fernandez S; Rendon A; Solovic I; Tadolini M; Viggiani P; Belilovski E; Boeree MJ; Cai Q; Davidavičienė E; Forsman LD; De Los Rios J; Drakšienė J; Duga A; Elamin SE; Filippov A; Garcia A; Gaudiesiute I; Gavazova B; Gayoso R; Gruslys V; Jonsson J; Khimova E; Madonsela G; Magis-Escurra C; Marchese V; Matei M; Moschos C; Nakčerienė B; Nicod L; Palmieri F; Pontarelli A; Šmite A; Souleymane MB; Vescovo M; Zablockis R; Zhurkin D; Alffenaar JW; Caminero JA; Codecasa LR; García-García JM; Esposito S; Saderi L; Spanevello A; Visca D; Tiberi S; Pontali E; Centis R; D'Ambrosio L; van den Boom M; Sotgiu G; Migliori GB Pulmonology; 2021; 27(5):403-412. PubMed ID: 33753021 [TBL] [Abstract][Full Text] [Related]
39. Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study. Franke MF; Khan P; Hewison C; Khan U; Huerga H; Seung KJ; Rich ML; Zarli K; Samieva N; Oyewusi L; Nair P; Mudassar M; Melikyan N; Lenggogeni P; Lecca L; Kumsa A; Khan M; Islam S; Hussein K; Docteur W; Chumburidze N; Berikova E; Atshemyan H; Atwood S; Alam M; Ahmed S; Bastard M; Mitnick CD Am J Respir Crit Care Med; 2021 Jan; 203(1):111-119. PubMed ID: 32706644 [No Abstract] [Full Text] [Related]
40. Applicability of the shorter 'Bangladesh regimen' in high multidrug-resistant tuberculosis settings. Sotgiu G; Tiberi S; Centis R; D'Ambrosio L; Fuentes Z; Zumla A; Migliori GB Int J Infect Dis; 2017 Mar; 56():190-193. PubMed ID: 27816662 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]